ERAS
Erasca, Inc.
$11.24
-0.36
(-3.15%)
Mkt Cap
3.50B
Volume
2,492,149
52W Range
1.06-24.28
Sector
Healthcare
Beta
0.68
EPS (TTM)
-0.93
P/E Ratio
-8.47
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (124.55M) | (161.65M) | (125.04M) | (242.81M) | (122.76M) | (101.66M) | (12.04M) |
| EPS | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| Free Cash Flow | (95.58M) | (131.98M) | (102.99M) | (119.81M) | (98.48M) | (71.38M) | (10.97M) |
| FCF / Share | -0.34 | -0.56 | -0.69 | -0.98 | -0.83 | -0.60 | -0.09 |
| Operating CF | (95.45M) | (109.42M) | (101.22M) | (103.26M) | (79.60M) | (32.69M) | (10.38M) |
| Total Assets | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M | 124.83M | 55.51M |
| Total Debt | 47.14M | 51.89M | 55.86M | 55.10M | 18.79M | 2.99M | 3.69M |
| Cash & Equiv | 73.81M | 67.74M | 93.08M | 284.22M | 360.49M | 65.38M | 29.58M |
| Book Value | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M | 107.42M | (13.60M) |
| Return on Equity | -0.38 | -0.38 | -0.39 | -0.59 | -0.27 | -0.95 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (183.44M) | (29.09M) | (30.61M) | (33.88M) | (30.97M) | (32.23M) | (31.20M) | (63.20M) | (35.02M) | (29.70M) | (30.36M) | (31.78M) |
| EPS | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.11 | -0.11 | -0.29 | -0.23 | -0.20 | -0.20 | -0.21 |
| Free Cash Flow | (27.42M) | (21.72M) | (21.66M) | (20.56M) | (31.64M) | (24.56M) | (22.42M) | (29.20M) | (33.29M) | (24.87M) | (24.36M) | (26.20M) |
| FCF / Share | -0.09 | -0.08 | -0.08 | -0.07 | -0.11 | -0.09 | -0.08 | -0.13 | -0.22 | -0.16 | -0.16 | -0.17 |
| Operating CF | (27.38M) | (21.71M) | (21.66M) | (20.53M) | (31.55M) | (24.56M) | (22.42M) | (29.18M) | (33.25M) | (24.79M) | (24.12M) | (25.95M) |
| Total Assets | 461.23M | 396.15M | 420.40M | 445.39M | 471.24M | 502.53M | 528.90M | 525.74M | 370.02M | 395.30M | 419.41M | 440.66M |
| Total Debt | 45.95M | 47.14M | 48.29M | 49.42M | 50.81M | 51.89M | 52.94M | 53.97M | 65.97M | 55.86M | 56.76M | 57.64M |
| Cash & Equiv | 47.26M | 73.81M | 70.23M | 66.14M | 70.48M | 67.74M | 68.89M | 172.80M | 76.73M | 93.08M | 112.86M | 138.79M |
| Book Value | 393.53M | 325.17M | 347.89M | 372.26M | 399.50M | 423.50M | 450.04M | 451.09M | 288.41M | 316.69M | 338.98M | 362.70M |
| Return on Equity | -0.47 | -0.09 | -0.09 | -0.09 | -0.08 | -0.08 | -0.07 | -0.14 | -0.12 | -0.09 | -0.09 | -0.09 |
ERAS News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference